PennantPark Investment Corp
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About PennantPark Investment Corp
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
Frequently asked questions
To buy PennantPark Investment Corp stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for PennantPark Investment Corp by name or ticker, choose the number of shares, and place your order.
The ticker symbol for PennantPark Investment Corp is PNNT:xnys. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
PennantPark Investment Corp has its primary listing on New York Stock Exchange. You can trade PennantPark Investment Corp with a Saxo account, alongside thousands of other stocks worldwide.
Yes, PennantPark Investment Corp is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include PennantPark Investment Corp as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like PennantPark Investment Corp.